帕罗西汀和氯丙咪嗪治疗惊恐障碍——随机双盲平行对照研究  

Paroxctine versus clomipramine for the Treatment of Panic disorders-a doublc-blind randomized study

作　　者：张海音[1] 张鸿燕[2] 赵靖平[3] 马崔 李鸣[5] 陶明[6] 徐文璇 张明园[1] 

机构地区：[1]上海市精神卫生中心,200030 [2]北京大学精神卫生研究所 [3]湖南医科大学精神卫生研究所 [4]广州市精神病院 [5]苏州广济医院 [6]杭州市第七人民医院 [7]北京协和医院

出　　处：《中国心理卫生杂志》2000年第6期410-413,共4页Chinese Mental Health Journal

基　　金：中美天津史克制药有限公司资助

摘　　要：目的 :研究帕罗西汀和氯丙咪嗪治疗惊恐障碍的有效性和安全性。方法 :双盲随机平行对照的多中心研究。为期 10周。以临床判断及PASS、HAMA、SDS等量表评定临床效果 ,以TESS评定不良反应。结果 :入组 73例 (帕罗西汀 38例 ,氯丙咪嗪 35例 ) ,因副反应而退组 5例 (分别为 1例和 4例 ) ,完成研究者6 8例 (分别为 37例和 31例 )。平均最高剂量为 :帕罗西汀 43 5mg/d ,氯丙咪嗪 15 9 7mg/d。临床判断 ,帕罗西汀和氯丙咪嗪的显效率为 6 2 2 %和 6 4 5 %。至治疗结束时 ,83 8%和 87 1%的病人已无完全性惊恐发作。自第 2周末起 ,PASS总分已显著下降。两种药物的效果无明显差异。副反应的发生率 ,帕罗西汀组18 4% ,远低于氯丙咪嗪组的 42 9%。结论 :帕罗西汀是一种疗效好、安全性高的治疗惊恐障碍的药物。Objective: To compare the efficacy and safety of paroxetine and clomipramine in the treatment of panic disorder.Method: A 10 weeks multi-centred double-blind randomized study was designed.The efficacy was evaluated by clinical judgment,PASS,HAMA and SDS.The safety was assessed in terms of TESS. Results: 73 cases of panic disorder were enrolled and 5 cases were withdrawn due to intolerance of side effects:1 case from group of paroxetine and 4 cases from group of clomipramine,Among complete cases,37 were in the treatment of paroxetine and 31 were in clomipramine,According the judgment of clinicians,the marked improved rate was 62.2% for paroxeline and 64.5% for clomipramine.By the end of this study,the rate of free of panic attack auack was 83.8% for paroxetine and 87.1% for clomipramine,The therapeutic effect was shown from the end of second week in both group However there was no significant difference in any efficacy measurement between two groups.Paroxetine group had much lower incidence of sidc effect(18.7%)than that of clomipramine(42.9%),in particularly the incidence of tachycardia and dry mouth.Conclusion: Paroxetine is one of efficient and high-safety drug in treatment of panic disorder.

关 键 词：帕罗西汀 氯丙咪嗪 治疗 惊恐障碍 药物疗法 

分 类 号：R749.790.5[医药卫生—神经病学与精神病学]